Antegenes: Funding, Investors & Team (Sep 2026)
Antegenes’ novel genetic tests assess a patient’s personal cancer risks, and include clinical recommendations for personalized cancer prevention. The tests are based on innovative polygenic risk score technology which helps to clarify a person’s genetic predispositions to cancer. It therefore allows for more accurate prevention and early detection measures – crucial in the fight with cancer. The tests are currently being used to determine the genetic risk for four cancers: breast cancer, prostate cancer, colon cancer, and skin melanoma.
Antegenes has raised $2.2M across 2 funding rounds on record, the most recent a Seed of $1.6M announced in Aug 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Antegenes Company Profile and Key Stats
Latest funding round on record: Aug 2022.
Antegenes Funding Rounds
Antegenes raised $600k in a Seed announced in Nov 2021.
9 months later, a Seed of $1.6M was announced in Aug 2022.
Antegenes Founders and Leadership Team
Contact details for the Antegenes team: 1 of 1 has an email address on file.
Start 14-day free trial →Antegenes Funding Compared to Other Biotechnology Startups
Antegenes' latest round of $1.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Antegenes in Biotechnology and Tartu
Companies Similar to Antegenes
Gearbox Biosciences, a biotech firm located in Tartu, Estonia, specializes in offering innovative technology…
High-end biotechnology services and goods are provided by the Icosagen Group, a contract research…
Decomer Technology is develops a novel water-soluble and edible packaging material and products thereof.
Gelatex is a Techstars-backed materials technology company that invented the fastest technology for producing…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Antegenes Funding FAQs
What does Antegenes do?
Antegenes’ novel genetic tests assess a patient’s personal cancer risks, and include clinical recommendations for personalized cancer prevention. The tests are based on innovative polygenic risk score technology which helps to clarify a person’s genetic predispositions to cancer. It therefore allows for more accurate prevention and early detection measures – crucial in the fight with cancer. The tests are currently being used to determine the genetic risk for four cancers: breast cancer, prostate cancer, colon cancer, and skin melanoma.
How much funding has Antegenes raised?
Antegenes has raised $2.2M across 2 rounds on record. The most recent is a Seed of $1.6M announced in Aug 2022.
When did Antegenes last raise funding?
Antegenes' most recent funding round on record is a Seed of $1.6M, announced in Aug 2022.
Who is the CEO of Antegenes?
Peeter Padrik is listed as CEO at Antegenes.
Where is Antegenes headquartered?
Antegenes is based in Tartu, Tartumaa, Estonia.
How many employees does Antegenes have?
Antegenes is in the 11-50 employee band.
How does Antegenes' funding compare to other Biotechnology startups?
Antegenes' latest round of $1.6M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Antegenes Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Antegenes is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.